Amgen research cuts buck top pharma trend
This article was originally published in Scrip
Executive Summary
Amgen has now confirmed that it is to reduce its research and development employees by some 380 positions. The number represents just over a 2% reduction in Amgen�s total workforce, but around 10% of those involved in R&D. However, those observers who have welcomed the cuts as a sign that Amgen is bringing its R&D commitments into line with pharma industry norms, may need to re-examine the industry-wide spending data.